Incidence and outcomes of pulmonary hypertension in the Ireland

Sarah Cullivan, Denise Lennon, Salima Meghani, Caitriona Minnock, Brian McCullagh, Sean Gaine

ABSTRACT

Introduction Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality. The aim of this study is to define the characteristics of PH in the national PH unit (NPHU) in Ireland between 2010 and 2020.

Methods Cases of PH which were referred to the NPHU between 2010 and 2020 were included. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg at right heart catheterisation.

Results Four hundred and fifteen cases of PH were identified during the study period. Group 1 pulmonary arterial hypertension (PAH) accounted for 39% (n=163) of cases, with a calculated annual incidence of 3.11 per million population (95% CI 1.53 to 4.70). The leading PAH subgroup was connective tissue disease-associated PAH (CTD-PAH), which was responsible for 49% of PAH referrals. This was followed by idiopathic PAH, with an estimated annual incidence of 0.63 cases per million population. The mean age at PAH diagnosis was 56±15 years and 86% (n=111) received double-combination or triple-combination therapy within the first 12 months of diagnosis. The 1-year, 3-year and 5-year transplant-free survival for PAH was 89%, 75% and 65%. This was significantly lower for individuals with CTD-PAH relative to other PAH subgroups (p<0.05).

Discussion This study describes the incidence and outcomes of PH in Ireland. While the outcomes are comparable to other centres, the incidence of PAH and specific subgroups appears low, suggesting that improved disease awareness and case recognition are required. Furthermore, the survival of individuals with CTD-PAH is poor and requires additional exploration.

INTRODUCTION

Pulmonary hypertension (PH) is a heterogeneous disease of the pulmonary circulation, with an estimated prevalence of 1% of the global population.1 2 The clinical classification of PH categorises PH into five groups based on the underlying aetiology. These include group 1 pulmonary arterial hypertension (PAH), group 2 PH due to left heart disease, group 3 PH due to lung disease and/or hypoxia, group 4 PH caused by pulmonary vascular obstructions such as chronic thromboembolic PH (CTEPH) and group 5 PH with unclear and/or multifactorial mechanisms.3 A diagnosis of PH requires right heart catheterisation (RHC) and evidence of an mean pulmonary artery pressure (MPAP) ≥25 mm Hg. However, the haemodynamic definition is evolving and this threshold will be reduced to >20 mm Hg in forthcoming guidelines.4

There is a paucity of information regarding the characteristics of PH in Ireland. A study of incident, treatment naïve subjects with idiopathic PAH (IPAH), hereditary PAH (HPAH) and anorexigen-associated PAH diagnosed in Ireland and the UK between 2001 and 2009 revealed an estimated annual incidence of 1.1 cases per million population.5 These individuals typically presented with severe functional and haemodynamic impairment. The median age at diagnosis was 50 years and the 1-year, 3-year and 5-year survival was 92.7%, 73.3% and 61.1%.5 Since then, there has been no published data regarding the characteristics of PAH in Ireland, despite considerable advances in the field. Our understanding of the pathobiology, pathophysiology and epidemiology of PAH has evolved in recent years.6 Similarly, treatment options have expanded.
and PH has become a paradigm for a successful approach to rare respiratory diseases.4 The transforming landscape of PH will have implications for disease incidence and patient outcomes.

In the UK and Ireland, PH care is centralised, and patients must be referred to one of nine centres to receive a diagnosis and treatment with PH-specific therapy. The eight specialist PH centres in the UK are audited annually, resulting in contemporary information on PH epidemiology and survival. However, this is not the case in Ireland, as there is no formal national registry. Therefore, the objective of this study is to determine the characteristics of PH attending the national PH unit (NPHU) in Ireland between 2010 and 2020, with special consideration of incidence and outcomes.

METHODS

Cases of PH which were referred to the NPHU between 2010 and 2020 were included in this study. The NPHU was established in Dublin, Ireland in 2003 and is one of nine specialised PH centres between Ireland and the UK. It is the only PH referral centre in the Ireland. As the prescription of PH-specific therapy is restricted, all suspected cases of group 1 PAH and group 4 PH that are potentially amenable to these therapies should be referred and reviewed in the national centre. However, not all cases of group 2 or group 3 PH are typically referred to the NPHU as the PH-directed interventions are limited.

For study inclusion, RHC and evidence of a MPAP ≥25 mm Hg were required. Exclusion criteria included prevalent PH cases and cases with inadequate information. Inadequate information was defined as the availability of less than 50% of key parameters including WHO functional class (WHO FC), B type natriuretic peptide (BNP), 6 min walk distance (6MWD), RHC data, treatment characteristics and survival information. Information was collected from hospital charts and the electronic IT system. Patient demographics and clinical characteristics including FC, BNP, RHC parameters and lung function represent those performed at the time of PH diagnosis. Treatment characteristics refer to prescriptions within the first 12 months following diagnosis. The annual incidence was derived using population estimates from the central statistics office and the national census of the Ireland, which reported a population of 4,757,976 persons in 2016.7,8 The European Society of Cardiology/European Respiratory Society 2015 guidelines and risk stratification table are used in clinical practice.9

Statistical analysis was performed using GraphPad online statistical software. Continuous variables were expressed as means±SD and categorical variables as n (%). Median values and the IQR were used when the variables were not normally distributed. An unpaired t test was used to calculate the significance between means and a CI of 95% was chosen.10 A value less than 0.05 was considered statistically significant (p<0.05). Survival estimates were made using the Kaplan-Meier method, with comparisons performed by the log-rank test.

RESULTS

Study population

Four hundred and fifteen cases of PH were referred to the NPHU between 2010 and 2020 (online supplemental figure 1). The estimated annual incidence of PH during this period was 7.93 per million population (95% CI 5.40 to 10.46). Group 1 PAH accounted for 39% (n=163) of these cases. This was followed by group 2 PH (16%, n=69), group 4 (16%, n=67), group 3 (9%, n=39) and finally group 5 (6%, n=23). The remaining 13% (n=54) were defined as PH of mixed aetiology, as they could not be isolated to a single diagnostic group (table 1).

The calculated annual incidence of PAH was 3.11 per million population (95% CI 1.53 to 4.70). Within group 1, connective tissue disease-associated PAH (CTD-PAH) was the predominant subtype (49%, n=80), followed by IPAH (20%, n=33) and congenital heart disease-associated PAH (CHD-PAH) (13%, n=22) (table 2). The calculated annual incidence of PAH-CTD was 1.53 per million population (95% CI 0.42 to 2.64). The estimated annual incidence of IPAH was 0.63 per million population (95% CI -0.08 to -1.34), of drug-associated PAH was 0.06 per million population, of HPAH was 0.04 per million population and of CHD-associated PAH was 0.63 per million population (table 3).

Of the 80 subjects with CTD-PAH, 81% (n=65) had a diagnosis of systemic sclerosis, 15% (n=12) had mixed CTD, 3% (n=2) had systemic lupus erythematosus and 1 case was classified as undefined. The calculated incidence for CHD-PAH does not reflect the true incidence of this specific subgroup, as these patients are not consistently referred to the NPHU, and is typically managed separately in adult congenital cardiology clinics.

The mean age at PAH-CTD diagnosis was 64±11 (median 66) years and 56±17 years (median 61) for IPAH. Individuals with IPAH demonstrated a mean BNP of 268 ng/L (SD ±295), 6MWD of 392 m (SD ±137) and 73% were stratified as intermediate or high risk at diagnosis (table 2).

The pulmonary vascular resistance was significantly higher in patients with group 1 PAH relative to groups 2, 3, 5 PH and those with mixed disease (p<0.05), but not group 4 PH (p=0.27). Additional patient characteristics are described in table 1 and table 2. Reducing the diagnostic threshold of PH from a mPAP threshold of >25 mm Hg to >20 mm Hg identified an additional 18 cases (7 with group 2 PH, 5 with CTEPH and a further 6 with PH of mixed aetiology).

Treatment

Sixty-eight per cent (n=111) of subjects with PAH received combination therapy in the first 12 months following diagnosis. Triple combination therapy regimens included oral or nebulised prostacyclin and were prescribed in
Table 1 Overview of characteristics of individuals diagnosed with pulmonary hypertension in the NPHU between 2010 and 2020

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
<th>Group 5</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>163</td>
<td>69</td>
<td>39</td>
<td>67</td>
<td>23</td>
</tr>
<tr>
<td>Sex: female n (%)</td>
<td>125 (77)</td>
<td>45 (65)</td>
<td>20 (51)</td>
<td>29 (43)</td>
<td>9 (39)</td>
</tr>
<tr>
<td>Age (years): mean±SD</td>
<td>56±15</td>
<td>69±10</td>
<td>64±13</td>
<td>61±16</td>
<td>57±13</td>
</tr>
<tr>
<td>WHO functional class: % I/II/III/IV</td>
<td>1/29/56/14</td>
<td>1/26/49/22</td>
<td>0/15/56/28</td>
<td>1/28/64/7</td>
<td>0/22/74/4</td>
</tr>
</tbody>
</table>

Right heart catheterisation

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
<th>Group 5</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRAP (mm Hg)</td>
<td>9±6</td>
<td>11±6</td>
<td>6±3</td>
<td>9±5</td>
<td>8±6</td>
<td>11±6</td>
</tr>
<tr>
<td>mPAP (mm Hg)</td>
<td>46±15</td>
<td>42±12</td>
<td>39±11</td>
<td>44±9</td>
<td>39±12</td>
<td>40±12</td>
</tr>
<tr>
<td>PAWP (mm Hg)</td>
<td>11±5</td>
<td>20±7</td>
<td>10±5</td>
<td>11±4</td>
<td>12±6</td>
<td>15±7</td>
</tr>
<tr>
<td>CO (L/min)</td>
<td>4±1</td>
<td>5±1</td>
<td>4±2</td>
<td>4±1</td>
<td>5±1</td>
<td>4±1</td>
</tr>
<tr>
<td>PVR (WU)</td>
<td>10±7</td>
<td>5±3</td>
<td>7±4</td>
<td>9±4</td>
<td>6±5</td>
<td>7±5</td>
</tr>
<tr>
<td>DLCO, % predicted</td>
<td>49±23</td>
<td>46±15</td>
<td>35±14</td>
<td>67±13</td>
<td>42±18</td>
<td>41±16</td>
</tr>
</tbody>
</table>

PH therapy within 12 months of diagnosis: n (%) | 148 (91) | 33 (48) | 29 (74) | 54 (81) | 17 (74) | 35 (65) |

| Monotherapy | 37 (23) | 29 (42) | 23 (59) | 38 (57) | 8 (35) | 26 (48) |
| Double combination therapy | 88 (54) | 4 (6) | 5 (13) | 15 (22) | 7 (30) | 7 (13) |
| Triple combination therapy | 23 (14) | 0 | 1 (3) | 1 (1) | 2 (9) | 1 (2) |
| Balloon atrial septostomy | 3 (2) | 0 | 0 | 0 | 0 | 0 |
| Lung transplantation | 5 (3) | 0 | 2 (5) | 0 | 1 (4) | 0 |

Survival

1-year, 3-year and 5-year survival, % | 89, 75, 65 | 94, 88, 75 | 66, 33, 14 | 93, 79, 64 | 100, 75, 75 | 89, 71, 64 |

Median follow-up (IQR): years | 3 (1–5) | 2 (1–4) | 1.5 (1–3) | 3 (2–5) | 2 (1–3) | 3 (1–4) |

FC, BNP, RHC parameters and lung function were collected at diagnosis. WHO FC was available for all 415 patients. Of note data were incomplete for the following parameters: BNP not available for 12%, mRAP in 39%, mPAP in 9%, PAWP in 19%, CO in 46%, PVR in 54% and DLCO in 52%.

Survival data were available for 19 (86%) individuals with CHD-PAH.

BNP, B-type natriuretic peptide; CO, cardiac output; DLCO, diffusion capacity for carbon monoxide; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.
Table 2  Characteristics of pulmonary arterial hypertension subgroups at the time of diagnosis, with a specific focus on demographics and treatment patterns

<table>
<thead>
<tr>
<th></th>
<th>CTD-PAH</th>
<th>IPAH</th>
<th>CHD-PAH</th>
<th>PoPH</th>
<th>PVOD</th>
<th>DPAH</th>
<th>CCB</th>
<th>HPAH</th>
<th>HIV-PAH</th>
<th>HHT-PAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>80 (49)</td>
<td>33 (20)</td>
<td>22 (13)</td>
<td>11 (7)</td>
<td>5 (3)</td>
<td>3 (2)</td>
<td>3 (2)</td>
<td>2 (1)</td>
<td>2 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Sex: female n (%)</td>
<td>72 (90)</td>
<td>26 (79)</td>
<td>13 (59)</td>
<td>2 (18)</td>
<td>2 (40)</td>
<td>3 (100)</td>
<td>3 (100)</td>
<td>2 (100)</td>
<td>2 (100)</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Age (years): mean±SD</td>
<td>64±11</td>
<td>56±17</td>
<td>55±21</td>
<td>47±9</td>
<td>69±9</td>
<td>58±15</td>
<td>34±13</td>
<td>46±14</td>
<td>45±1</td>
<td>47±29</td>
</tr>
<tr>
<td>WHO functional class: % I/II/III/IV</td>
<td>0/22/60/18</td>
<td>3/24/55/18</td>
<td>0/50/50/0</td>
<td>0/36/64/0</td>
<td>0/20/40/40</td>
<td>0/33/33/33</td>
<td>0/67/33/0</td>
<td>0/0/100/0</td>
<td>0/50/50/0</td>
<td>0/50/50/0</td>
</tr>
<tr>
<td>BNP (ng/L): mean±SD</td>
<td>611±795</td>
<td>268±295</td>
<td>271±348</td>
<td>63±40</td>
<td>417±675</td>
<td>1330±1800</td>
<td>53±41</td>
<td>298±87</td>
<td>---</td>
<td>187±127</td>
</tr>
<tr>
<td>Risk stratification: % Low/intermediate/high risk</td>
<td>8/61/31</td>
<td>27/45/28</td>
<td>27/55/18</td>
<td>9/91/0</td>
<td>20/60/20</td>
<td>33/33/33</td>
<td>33/67/0</td>
<td>0/50/50</td>
<td>50/50/0</td>
<td>0/100/0</td>
</tr>
<tr>
<td>Right heart catheterisation (mean±SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mPAP (mm Hg)</td>
<td>43±11</td>
<td>50±12</td>
<td>51±25</td>
<td>51±17</td>
<td>38±14</td>
<td>43±25</td>
<td>38±1</td>
<td>49±0</td>
<td>44±6</td>
<td>46±0</td>
</tr>
<tr>
<td>PAWP (mm Hg)</td>
<td>11±3</td>
<td>8±3</td>
<td>13±5</td>
<td>12±7</td>
<td>12±10</td>
<td>7±0</td>
<td>7±2</td>
<td>8±0</td>
<td>12±0</td>
<td>---</td>
</tr>
<tr>
<td>CO (L/min)</td>
<td>4±1</td>
<td>4±2</td>
<td>4±1</td>
<td>5±1</td>
<td>4±0</td>
<td>3±0</td>
<td>5±1</td>
<td>2±0</td>
<td>4±0</td>
<td>9±0</td>
</tr>
<tr>
<td>PVR (WU)</td>
<td>9±4</td>
<td>12±7</td>
<td>12±13</td>
<td>6±3</td>
<td>8±0</td>
<td>13±0</td>
<td>6±1</td>
<td>18±0</td>
<td>15±0</td>
<td>---</td>
</tr>
<tr>
<td>DLCO, % predicted</td>
<td>35±14</td>
<td>69±20</td>
<td>73±21</td>
<td>50±6</td>
<td>43±13</td>
<td>19±0</td>
<td>88±0</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>PH therapy: n (%)</td>
<td>79 (99)</td>
<td>32 (97)</td>
<td>14 (64)</td>
<td>9 (82)</td>
<td>5 (100)</td>
<td>3 (100)</td>
<td>1 (33)</td>
<td>2 (100)</td>
<td>2 (100)</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Monotherapy</td>
<td>20 (25)</td>
<td>4 (12)</td>
<td>4 (29)</td>
<td>4 (44)</td>
<td>2 (40)</td>
<td>1 (33)</td>
<td>1 (100)</td>
<td>0</td>
<td>1 (50)</td>
<td>0</td>
</tr>
<tr>
<td>PD5 inhib.</td>
<td>10 (50)</td>
<td>4 (100)</td>
<td>2 (50)</td>
<td>3 (75)</td>
<td>2 (100)</td>
<td>1</td>
<td>1 (100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ERA</td>
<td>10 (50)</td>
<td>0</td>
<td>2 (50)</td>
<td>1 (25)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Double combination therapy</td>
<td>45 (56)</td>
<td>22 (67)</td>
<td>9 (64)</td>
<td>5 (56)</td>
<td>2 (40)</td>
<td>1 (33)</td>
<td>0</td>
<td>2 (100)</td>
<td>1 (50)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>PD5 inhib. and ERA</td>
<td>44 (98)</td>
<td>21 (95)</td>
<td>9 (100)</td>
<td>5 (100)</td>
<td>2 (100)</td>
<td>1 (100)</td>
<td>0</td>
<td>2 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>sGCS+ERA</td>
<td>0</td>
<td>1 (5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ERA+PGI2</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Triple combination therapy</td>
<td>14 (18)</td>
<td>6 (18)</td>
<td>1 (7)</td>
<td>0</td>
<td>1 (20)</td>
<td>1 (33)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PD5 inhib.+ERA + neb PGI2</td>
<td>12 (86)</td>
<td>4 (67)</td>
<td>1 (100)</td>
<td>0</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PD5 inhib.+ERA + oral PGI2</td>
<td>2 (14)</td>
<td>2 (33)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Data were incomplete for the following characteristics and parameters at the time of diagnosis: mPAP was missing for 22 (13%) subjects, PAWP for 22 (13%), CO for 85 (52%), PVR for 95 (58%) and DLCO was missing in 87 (53%) cases. Of note: While mPAP was unavailable at diagnosis for 13% of PAH subjects, a subsequent RHC with evidence of a mPAP >25 mm Hg was available for all subjects, but not included in this analysis. Inadequate data were omitted and replaced by ‘---’.

BNP, B-type natriuretic peptide; CCB, long-term responsive to calcium channel blockers PAH; CHD-PAH, congenital heart disease associated PAH; CO, cardiac output; CTD-PAH, connective tissue disease associated pulmonary arterial hypertension; DLCO, diffusion capacity for carbon monoxide; DPAH, drug-associated PAH; ERA, endothelin receptor antagonist; HHT-PAH, hereditary haemorrhagic telangiectasia associated PAH; HIV-PAH, HIV associated PAH; HPAH, hereditary PAH; PD5 inhib, phosphodiesterase type-5 inhibitor; PAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; neb, nebulised; PAWP, pulmonary artery wedge pressure; PGI2, prostacyclin; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; PVOD, pulmonary veno occlusive disease; PVR, pulmonary vascular resistance; sGCS, soluble guanylate cyclase stimulator.
14% (n=24) of PAH cases (table 2). No parenteral prosta-
tacyclin therapy was prescribed in the first 12 months of
diagnosis.
Of the 67 subjects with CTEPH, 31% (n=21) under-
going pulmonary endarterectomy (PEA), 4% (n=3) underwent
balloon pulmonary angioplasty and 1% (n=1) underwent
both procedures.

Survival
The 1-year, 3-year and 5-year transplant-free survival
for subjects with PAH was 89%, 75% and 65%, respec-
tively. This was significantly lower for individuals with
CTD-PAH, when compared with other PAH subgroups,
including IPAH (p=0.0009) (table 3). This was most

notable for individuals with systemic sclerosis-associated
PAH (SSc-PAH) as illustrated in figure 1. The 1-year,
3-year and 5-year survival for individuals with group 3 PH
was significantly lower than all other groups, including
PAH (p<0.0001) (online supplemental figure 2). Balloon
atrial septostomy (BAS) was performed in a total of three
subjects and eight (2%) individuals with PH underwent
lung transplantation during the study period.

DISCUSSION
PH is a disease of the pulmonary circulation that encom-
passes a spectrum of conditions that differ in characteris-
tics.1 2 This study addressed the paucity of data regarding
the clinical characteristics of PH in the Ireland and
provide insights into the incidence and outcomes of PH in
the preceding decade. This is particularly relevant given
the transforming landscape of PH, with evolving patient
demographics and expanding treatment options.11
This study revealed an estimated annual incidence
of PAH in Ireland of 3.11 cases per million population.
While the true global incidence of PAH is unknown, data
from national systematic registries in Europe suggest
that the annual incidence is between 5.8 to 13.7 cases
per million population (table 4).12–15 Epidemiological
estimates derived from non-systematic sources typically
report lower estimates 16 and this may have contributed
to the results in this study, which were derived from a
local database. Interestingly, the estimated annual inci-
dence of PAH in the UK is 6.1–7.6 cases per million popula-
tion.14 16 17 As Ireland shares similar demographic
characteristics with the UK, this may reflect the success
of the national UK audit of PH, which is a current and
authoritative source of epidemiological data.16 A national
systematic registry in Ireland would be valuable to ensure
structured and consistent data collection and to facilitate
national and international comparisons. It is also plau-
sible that the calculated incidence of PAH in Ireland may

Table 3 1-year, 3-year and 5-year survival of individuals with PAH, with a specific focus on CTD-PAH, IPAH, CHD-PAH and PoPH

<table>
<thead>
<tr>
<th></th>
<th>PAH</th>
<th>CTD-PAH</th>
<th>IPAH</th>
<th>CHD-PAH</th>
<th>PoPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>160*</td>
<td>80</td>
<td>33</td>
<td>19*</td>
<td>11</td>
</tr>
<tr>
<td>Annual incidence</td>
<td>3.11</td>
<td>1.53</td>
<td>0.63</td>
<td>0.63*</td>
<td>0.21</td>
</tr>
<tr>
<td>Survival, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 year</td>
<td>89</td>
<td>83</td>
<td>100</td>
<td>100</td>
<td>91</td>
</tr>
<tr>
<td>3 year</td>
<td>75</td>
<td>62</td>
<td>100</td>
<td>100</td>
<td>81</td>
</tr>
<tr>
<td>5 year</td>
<td>65</td>
<td>47</td>
<td>95</td>
<td>91</td>
<td>81</td>
</tr>
<tr>
<td>Median (IQR) follow-up, years</td>
<td>3 (1–5)</td>
<td>2.5 (1–4)</td>
<td>3 (2–7)</td>
<td>4 (3–7)</td>
<td>5 (3–6.5)</td>
</tr>
</tbody>
</table>

The median follow-up in years and IQR is also provided for each subgroup.
*The calculated incidence for CTD-PH does not reflect the true incidence of this particular subgroup as these patients are an exception in that they are not consistently referred to the NPHU. Survival data were not available for three subjects with CTD-PAH. Annual incidence is reported per million population (pmp).
CHD-PAH, congenital heart disease PAH; CTD-PAH, connective tissue disease PAH; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PoPH, portopulmonary pulmonary hypertension.

Figure 1 Kaplan-Meier curve illustrating the cumulative survival of patients with congenital heart disease-associated pulmonary arterial hypertension (PAH-CHD), idiopathic pulmonary arterial hypertension (IPAH) and systemic sclerosis-associated PAH (PAH-SSc). The cumulative 5-year survival was significantly lower in patients with PAH-SSc relative to IPAH and PAH-CHD (p<0.05).
Table 4  Incidence and survival of PAH in Ireland and other European countries

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with PAH, n</td>
<td>163</td>
<td>374</td>
<td>1344</td>
<td>674</td>
<td>866</td>
<td>457</td>
<td>191</td>
<td>685</td>
<td>263</td>
<td>130</td>
<td>134</td>
<td>46</td>
</tr>
<tr>
<td>Age (years), mean±SD</td>
<td>56±15</td>
<td>52±13*</td>
<td>59±17</td>
<td>50±15</td>
<td>45±17</td>
<td>67↑</td>
<td>52±17</td>
<td>51±16</td>
<td>61±18</td>
<td>65↑</td>
<td>50±21</td>
<td>43±16</td>
</tr>
<tr>
<td>Female, %</td>
<td>77%</td>
<td>70%</td>
<td>65.3%</td>
<td>71%</td>
<td>64%</td>
<td>65%</td>
<td>65%</td>
<td>67%</td>
<td>73%</td>
<td>58.2%</td>
<td>65.2%</td>
<td></td>
</tr>
</tbody>
</table>

Annual incidence

| PAH      | 3.11 | 7.6 | 6.1 | 2.4 | 3.7 | - | 10.7 | - | 3.9 | 13.7 | - | 1.5 |
| IPAH     | 0.63 | 2.6 | 2.1 | - | 1.2 | 5‡ | 6.2‡ | - | 2.4 | 7.6 | - | - |
| CTD-PAH  | 1.53 | 2.8 | 2.4 | - | - | - | - | - | 1.0 | - | - | - |

Survival PAH, %

| 1 year | 89 | - | 88 | 87 | 87 | 85 | 89 | 88.2 | - | 88 | 86.4 | 93.5 |
| 3 year | 75 | - | 68 | 67 | 75 | 71 | 74 | 72.2 | - | 73.3 | 72.9 | - |
| 5 year | 65 | - | - | - | 65 | 59 | - | 59.4 | - | 58.1 | 65.4 | - |

Survival IPAH, %

| 1 year | 100 | - | - | 89§ | 89 | - | 85‡ | 89.7 | - | - | - | - |
| 3 year | 100 | - | 63 | 69§ | 77 | - | 62‡ | 76.2 | - | - | - | - |
| 5 year | 95 | - | - | - | 68 | - | - | 65.3 | - | - | - | - |

Survival CTD-PAH, %

| 1 year | 83 | - | - | - | - | - | - | 85.3 | - | - | - | - |
| 3 year | 62 | - | 54 | - | - | - | - | 65.6 | - | - | - | - |
| 5 year | 47 | - | - | - | - | - | - | 50.9 | - | - | - | - |

*The annual incidence is calculated per million population. Age is displayed as mean and SD unless otherwise specified.
*Female mean age (SD).
†Median.
‡Incidence reflects IPAH and HPAH combined.
§Incidence reflects IPAH, HPAH and Anorexigen-associated PAH.
CTD-PAH, connective tissue disease associated PAH; IPAH, idiopathic PAH; PAH, pulmonary arterial hypertension.

[^a]: Scotland
[^b]: ASPIRE
[^c]: France
[^d]: SPAHR
[^e]: Giessen
[^f]: SPAHR
[^g]: COMPERA
[^h]: Latvia
[^i]: Denmark
[^j]: Portugal
[^k]: Portugal
[^l]: Portugal
reflect suboptimal disease recognition and referral and this requires further exploration.

The characteristics of PAH subgroups in Ireland also differ from other centres. PH registries from Europe and the USA generally report a predominance of IPAH within group 1 PAH, which is followed by PAH-CTD. In this study, the leading subgroup of PAH was PAH-CTD, which was responsible for 49% of PAH referrals (table 2). IPAH accounted for only 20% (n=33) of PAH cases, and the estimated annual incidence was low at 0.63 cases per million population. While it was the predominant subgroup, the incidence of PAH-CTD remained below UK estimates, at 1.53 versus 2.4 annual cases per million population. Therefore, rather than suggesting an abundance of PAH-CTD in Ireland, this data suggest suboptimal recognition of other PAH subgroups. Enhanced recognition of PAH-CTD may be attributed to screening tools such as the DETECT algorithm for SSC. However, as 82% of individuals with SSC-PAH reported FC III or IV symptoms at diagnosis and 32% had evidence of right heart failure, additional work is required to optimise the use of such screening tools in asymptomatic subjects. Ensuring adequate knowledge of CTD-PAH and access to RHC are additional important considerations.

The expansion of treatment options for PAH has been transformative for PAH care. Ninety-nine per cent of individuals with CTD-PAH and 97% of those with IPAH received PH-specific therapy within the first 12 months of diagnosis. Triple combination therapy for PAH comprised of oral or nebulised prostacyclin and there were no parenteral regimens commenced in this initial period. BAS was performed as a palliative procedure for three subjects with PAH and approximately 2% of subjects with PH underwent lung transplantation. Lung transplantation for this indication was somewhat below international statistics of 4.5%, but above UK estimates of 1%. Outcomes have improved substantially for individuals with PAH and the 1-year, 3-year and 5-year survival was 89%, 75% and 65% in this study. This is comparable to other European centres and largely reflects the evolution of management strategies and advancements in therapeutics in the preceding decades (table 4). Unfortunately, these improved outcomes did not translate to all PAH subgroups. Individuals with CTD-PAH and, in particular, SSC-PAH had distinctly worse survival when compared with those with IPAH. Notably, individuals with SSC-PAH were older at diagnosis (p<0.001) and had significantly higher BNP (p=0.0173) and PAWP (p<0.001) relative to those with IPAH. Furthermore, the diffusion capacity for carbon monoxide (DLCO) was markedly reduced in individuals with SSC-PAH at 35±14 (p<0.001). These characteristics may have contributed to the observed outcomes. In particular, older age has been associated with an attenuated response to PAH therapies and DLCO is an independent predictor of survival in PAH.

This study is limited by its retrospective nature and by missing data. Furthermore, only PH cases that were referred to the NPHU or attended the outpatient department were included in this study and, therefore, some cases may have been missed. Furthermore, patients with CHD-PAH are typically managed by congenital cardiology specialists and only select cases are referred to the NPHU. Therefore, the incidence of CHD-PAH reported in this article underestimates the incidence of PAH-CHD in Ireland. Irrespective, this study provides important insights into the incidence and outcomes of PH in Ireland. While the outcomes of PAH in Ireland are comparable to other centres, the incidence appears low. Improved disease awareness, increased case recognition and a national registry may be helpful to address this. Furthermore, while the outcomes of IPAH have improved, the survival of those with SSC-PAH is poor and requires exploration.

CONCLUSION

This study describes the incidence and outcomes of PH in Ireland and suggests that improved disease awareness and case recognition are required. The 1-year, 3-year and 5-year transplant-free survival for PAH was 89%, 75% and 65% during the study period. The outcomes of individuals with SSC-PAH and group 3 PH were poor and require additional attention and intervention.

Contributors SC and SG. All authors contributed equally to manuscript preparation.

Funding No funding was received for this work.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. N/A.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


